SESebastian Ewen

Sebastian Ewen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sebastian Ewen has a total of 127 co-authors. Here are the top co-authors by number of shared publications:

  • Michael Böhm

    Clinic of Internal Medicine III (Cardiology, Angiology and Intensive Care Medicine), Saarland University Medical Center, Universitätsklinikum des Saarlandes, Saarland University, Homburg, Germany

    16 shared publications
  • Felix Mahfoud

    Clinic of Internal Medicine III (Cardiology, Angiology and Intensive Care Medicine), Saarland University Medical Center, Universitätsklinikum des Saarlandes, Saarland University, Homburg, Germany

    14 shared publications
  • Felix Mahfoud

    University Hospital Basel

    12 shared publications
  • Lucas Lauder

    Clinic of Internal Medicine III (Cardiology, Angiology and Intensive Care Medicine), Saarland University Medical Center, Universitätsklinikum des Saarlandes, Saarland University, Homburg, Germany

    7 shared publications
  • Christian Ukena

    Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Universität des Saarlandes, Homburg, Saar, Germany

    6 shared publications
  • Dominik Linz

    Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre , Maastricht

    6 shared publications

Latest Publications

  • Top Cited Papers

    Hypertension management in patients with cardiovascular comorbidities

    by Lucas Lauder, Felix Mahfoud, Michel Azizi, Deepak L Bhatt, Sebastian Ewen, Kazuomi Kario, Gianfranco Parati, Patrick Rossignol, Markus P Schlaich, Koon K Teo, et al.

    Arterial hypertension is a leading cause of death globally. Due to ageing, the rising incidence of obesity, and socioeconomic and environmental changes, its incidence increases worldwide. Hypertension commonly coexists with Type 2 diabetes, obesity, dyslipidaemia, sedentary lifestyle, and smoking leading to risk amplification. Blood pressure lowering by lifestyle modifications and antihypertensive drugs reduce cardiovascular (CV) morbidity and mortality. Guidelines recommend dual- and triple-combination therapies using renin–angiotensin system blockers, calcium channel blockers, and/or a diuretic. Comorbidities often complicate management. New drugs such as angiotensin receptor-neprilysin inhibitors, sodium–glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, and non-steroidal mineralocorticoid receptor antagonists improve CV and renal outcomes. Catheter-based renal denervation could offer an alternative treatment option in comorbid hypertension associated with increased sympathetic nerve activity. This review summarises the latest clinical evidence for managing hypertension with CV comorbidities.


  • Manual zur Indikation und Durchführung spezieller echokardiographischer Anwendungen

    by Andreas Hagendorff, Andreas Helfen, Frank A. Flachskampf, Sebastian Ewen, Sebastian Kruck, Karl La Rosée, Jan Knierim, Jens-Uwe Voigt, Felix Kreidel, Wolfgang Fehske, et al.

    Zusammenfassung Das zweite Manual zur Indikation und Durchführung der Echokardiographie bezieht sich auf spezifische Anwendungen der Echokardiographie und besondere Fragestellungen bei speziellen Patientengruppen. Dabei stehen v. a. praktische Aspekte im Vordergrund. Methodisch etabliert sind die transösophageale Echokardiographie, die Stressechokardiographie und die Kontrastechokardiographie. Bei nahezu allen echokardiographischen Untersuchungen spielen aktuell 3‑D-Echokardiographie und Deformationsbildgebung eine Rolle. Das gesamte Spektrum der echokardiographischen Möglichkeiten wird derzeit in Notfall- und Intensivmedizin, bei der Überwachung und Führung von Katheterinterventionen, bei strukturellen Herzerkrankungen, bei herzchirurgischen Operationen, bei der Nachsorge von kardialen Unterstützungssystemen, bei kongenitalen Vitien im Erwachsenenalter und bei der Versorgung von hochinfektiösen Patienten in Pandemiezeiten angewandt. Die diagnostischen Fortschritte der konventionellen und modernen echokardiographischen Anwendungen stehen im Fokus dieses Manuals. Die 3‑D-Echokardiographie zur Charakterisierung der kardialen Morphologie und die Deformationsbildgebung zur Objektivierung der kardialen Funktion sind bei vielen Indikationen im klinischen Alltag etabliert. Die Stressechokardiographie zur Ischämie‑, Vitalitäts- und Vitiendiagnostik, die Bestimmung der koronaren Flussreserve und die Kontrastechokardiographie bei der linksventrikulären Wandbewegungsanalyse und kardialen Tumordetektion finden zunehmend klinische Anwendung. Wie für die konventionelle Echokardiographie im ersten Manual der Echokardiographie 2009 beschrieben, erfordert der Einsatz moderner echokardiographischer Verfahren die standardisierte Dokumentation und Akquisition bestimmter Bildsequenzen bei optimierter Geräteeinstellung, da korrekte und reproduzierbare Auswertungen nur bei guter Bildqualität möglich sind.


  • Open Access

    Long-Term Results up to 12 Months After Catheter-Based Alcohol-Mediated Renal Denervation for Treatment of Resistant Hypertension

    by Felix Mahfoud, Horst Sievert, Stefan Bertog, Lucas Lauder, Sebastian Ewen, Jean-Philippe Lengelé, Wojciech Wojakowski, Roland Schmieder, Markus van der Giet, Michael A. Weber, et al.

    Background: Primary results of this prospective, open-label, multicenter trial suggested that alcohol-mediated renal denervation with perivascular injection of dehydrated alcohol using the Peregrine System Infusion Catheter safely reduces blood pressure (BP) in patients with resistant hypertension. To date, maintenance of the BP-lowering effect beyond 6 months using this novel technology has not been reported. This article describes the final, 12-month follow-up data on the safety and efficacy of alcohol-mediated renal denervation in these patients. Methods: Forty-five patients with resistant hypertension on a stable regimen of on average 5.1±1.5 antihypertensive medications underwent successful bilateral renal denervation using the Peregrine Catheter with alcohol as the neurolytic agent (0.6 mL per renal artery). Apart from 2 vascular access pseudoaneurysms (both without sequelae), no major procedural complications occurred. Results: At 12 months post-procedure, mean 24-hour ambulatory systolic and diastolic BP were reduced by 10 mm Hg (95% CI, −16 to −5) and 7 mm Hg (−10 to −3), respectively ( P 2 [95% CI, −7.1 to −0.75]; P =0.02) was within the expected range. There were no cases of renal artery stenosis up to 12-month follow-up. Conclusions: Catheter-based chemical renal denervation with dehydrated alcohol using the Peregrine Catheter seems to safely reduce BP at follow-up of up to 12 months. Further randomized and sham controlled studies are underway to further validate these findings. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02570113.


  • Open Access

    SARS-CoV-2 vaccination in cardiothoracic organ transplant recipients: effective strategies wanted

    by Sebastian Ewen, Frank Neumann, Jörg T. Bittenbring, Wolfgang von Scheidt, Michael Böhm

  • Open Access

    Scientific publication activity during COVID-19 shutdown

    by Michael Böhm, Sebastian Ewen, Armin Schweitzer, Hugo Katus


  • Open Access

    Decline of emergency admissions for cardiovascular and cerebrovascular events after the outbreak of COVID-19

    by Viktoria Schwarz, Felix Mahfoud, Lucas Lauder, Wolfgang Reith, Stefanie Behnke, Sigrun Smola, Jürgen Rissland, Thorsten Pfuhl, Bruno Scheller, Michael Böhm, et al.

    Background: The spread of the novel coronavirus SARS-CoV-2 and the guidance from authorities for social distancing and media reporting lead to significant uncertainty in Germany. Concerns have been expressed regarding the underdiagnosing of harmful diseases. We explored the rates of emergency presentations for acute coronary syndrome (ACS) and acute cerebrovascular events (ACVE) before and after spread of SARS-CoV-2. Methods: We analyzed all-cause visits at a tertiary university emergency department and admissions for ACS and ACVE before (calendar weeks 1–9, 2020) and after (calendar weeks 10–16, 2020) the first coronavirus disease (COVID-19) case in the region of the Saarland, Germany. The data were compared with the same period of the previous year. Results: In 2020 an average of 346 patients per week presented at the emergency department whereas in 2019 an average of 400 patients presented up to calendar week 16 (p = 0.018; whole year 2019 = 395 patients per week). After the first COVID-19 diagnosis in the region, emergency department visit volume decreased by 30% compared with the same period in 2019 (p = 0.0012). Admissions due to ACS decreased by 41% (p = 0.0023 for all; Δ − 71% (p = 0.007) for unstable angina, Δ − 25% (p = 0.42) for myocardial infarction with ST-elevation and Δ − 17% (p = 0.28) without ST-elevation) compared with the same period in 2019 and decreased from 142 patients in calendar weeks 1–9 to 62 patients in calendar weeks 10–16. ACVE decreased numerically by 20% [p = 0.25 for all; transient ischemic attack: Δ − 32% (p = 0.18), ischemic stroke: Δ − 23% (p = 0.48), intracerebral haemorrhage: Δ + 57% (p = 0.4)]. There was no significant change in ACVE per week (p = 0.7) comparing calendar weeks 1–9 (213 patients) and weeks 10–16 (147 patients). Testing of 3756 samples was performed to detect 58 SARS-CoV-2 positive patients (prevalence 1,54%, thereof one patient with myocardial and two with cerebral ischemia) up to calendar week 16 in 2020. Conclusions: The COVID-19 pandemic was associated with a significant decrease in all-cause admission and admissions due to cardiovascular events in the emergency department. Regarding acute cerebrovascular events there was a numerical decrease but no significant difference.


  • Open Access

    Decline of emergency admissions for cardiovascular and cerebrovascular events after the outbreak of COVID-19

    by Viktoria Schwarz, Felix Mahfoud, Lucas Lauder, Wolfgang Reith, Stefanie Behnke, Sigrun Smola, Jürgen Rissland, Thorsten Pfuhl, Bruno Scheller, Michael Böhm, et al.

    Background The spread of the novel coronavirus SARS-CoV-2 and the guidance from authorities for social distancing and media reporting lead to significant uncertainty in Germany. As concerns have been expressed regarding the underdiagnosing of harmful diseases. We explored the rates of emergency presentations for acute coronary syndrome (ACS) and acute cerebrovascular events (ACVE) before and after spread of SARS-CoV-2. Methods We analyzed all-cause visits at a tertiary university emergency department and admissions for ACS and ACVE before (calendar weeks 1 to 9, 2020) and after (calendar weeks 10 to 16, 2020) the first coronavirus disease (COVID-19) case in the region of the Saarland, Germany. The data were compared with the same period of the previous year. Results In 2020 an average of 346 patients per week presented at the emergency department whereas in 2019 an average of 400 patients presented up to calendar week 16 (p=0.018; whole year 2019 = 395 patients per week). After the first COVID-19 diagnosis in the region, emergency department visit volume decreased by 30% compared with the same period in 2019 (p=0.0012). Admissions due to ACS decreased by 41% (p=0.0023 for all; Δ -71% (p=0.007) for unstable angina, Δ -25% (p=0.42) for myocardial infarction with ST-elevation and Δ -17% (p=0.28) without ST-elevation) compared with the same period in 2019 and decreased from 142 patients in calendar weeks 1 to 9 to 62 patients in calendar weeks 10 to 16. ACVE decreased numerically by 20% (p=0.25 for all; transient ischemic attack: Δ -32% (p=0.18), ischemic stroke: Δ -23% (p=0.48), intracerebral haemorrhage: Δ +57% (p=0.4)). There was no significant change in ACVE per week (p=0.7) comparing calendar weeks 1 to 9 (213 patients) and weeks 10 to 16 (147 patients). Testing of 3756 samples was performed to detect 58 SARS-CoV-2 positive patients (prevalence 1,54%, thereof one patient with myocardial and two with cerebral ischemia) up to calendar week 16 in 2020. Conclusions The COVID-19 pandemic was associated with a significant decrease in all-cause admission and admissions due to cardiovascular events in the emergency department. Regarding acute cerebrovascular events there was a numerical decrease but no significant difference.


  • Herzklappenvitien bei chronischer Niereninsuffizienz

    by S. Ewen, F. Mahfoud, L. Lauder, B. Scheller, M. Böhm


  • Anatomical and procedural determinants of ambulatory blood pressure lowering following catheter-based renal denervation using radiofrequency

    by Lucas Lauder, Sebastian Ewen, Abraham R. Tzafriri, Elazer R. Edelman, Bodo Cremers, Saarraaken Kulenthiran, Christian Ukena, Dominik Linz, Ingrid Kindermann, Costas Tsioufis, et al.